Format

Send to

Choose Destination
J Virol. 2015 Apr;89(8):4676-80. doi: 10.1128/JVI.00169-15. Epub 2015 Feb 11.

A triple-arginine motif in the amino-terminal domain and oligomerization are required for HIV-1 inhibition by human MX2.

Author information

1
Department of Infectious Diseases, King's College London, London, United Kingdom cgoujon@cpbs.cnrs.fr michael.malim@kcl.ac.uk.
2
Department of Infectious Diseases, King's College London, London, United Kingdom.

Abstract

We have employed molecular genetic approaches to understand the domain organization of the HIV-1 resistance factor myxovirus resistance 2 (MX2). First, we describe an essential triple-arginine motif in the amino-terminal domain. Second, we demonstrate that this 91-residue domain mediates antiviral activity when appended to heterologous proteins, and we provide genetic evidence that protein oligomerization is required for MX2 function. These insights will facilitate future work aiming to elucidate MX2's mechanism of action.

PMID:
25673704
PMCID:
PMC4442396
DOI:
10.1128/JVI.00169-15
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center